Magnolol was previously shown to inhibit genotoxicity induced by environmental mutagens both in vitro and in vivo. Here, we investigate the effects of the magnolol-containing kampo (traditional) medicines Hange-kobokuto, Dai-joki-to, and Goshaku-san, as well as Magnoliae Cortex, on the clastogenesis induced by benzo(a)pyrene (B(a)P) using the mouse micronucleus test. The mice were first treated with a single intraperitoneal injection of B(a)P, followed by a single oral dose of Hange-koboku-to, Dai-joki-to, Goshaku-san, or Magnoliae Cortex. Peripheral blood specimens were prepared 48 h after B(a)P administration and analyzed using the acridine orange (AO) technique. The anti-clastogenic mechanisms employed by the kampo medicines and Magnoliae Cortex were also investigated by evaluating in vivo CYP1A1 activity using the zoxazolamine paralysis test. Results show that Hange-koboku-to, Dai-joki-to, and Magnoliae Cortex, which contain high levels of magnolol, significantly inhibited the clastogenesis induced by B(a)P and sufficiently inhibited in vivo CYP1A1 activity. In contrast, Goshakusan, which contains low levels of magnolol, had little inhibitory effect on clastogenicity and in vivo CYP1A1 activity. These findings suggest that magnolol is a major contributor to the inhibition of B(a)P-induced clastogenesis, and that kampo medicines exert significant anti-clastogenic effects.
We have previously shown that magnolol (5,5Ј-diallyl-2,2Ј-dihydroxybiphenyl), which is isolated from the bark of Magnoliae Cortex, inhibits indirect mutagen-induced mutagenicity in the Ames test. 1) We have also demonstrated the clastogenicity of benzo(a)pyrene (B(a)P) in the mouse micronucleus test, 2) and the DNA-damaging properties of 3-amino-1-methyl-5H-pyrido [4,3-b] indole (Trp-P-2) during mouse single cell gel electrophoresis.
3) Therefore, magnolol may possess chemopreventative properties and contribute to the inhibition of carcinogenesis. Magnolol has been reported to exert various biological effects, such as preventing platelet aggregation through the inhibition of thromboxane formation, 4) scavenging hydroxyl radicals in UV-induced mutations of Salmonella typhimurium TA102, 5) blocking Ca 2ϩ -channels, 6) preventing inflammation through the inhibition of cyclooxygenase and lipooxygenase, 7) discouraging tumor development through inhibition of tumor cell invasion and induction of tumor cell apoptosis, 8, 9) inhibiting the promotion of carcinogenesis induced by 12-O-tetradecanoylphorbol-13-acetate, 10) reducing the inflammatory phase of the formalininduced licking response (antinociceptive effect), 11) improving the response to immunoglobulin E (IgE)-induced allergies, 12) and exerting a protective effect on sepsis-induced inflammation and intestinal dysmotility. 13) All of these effects are also thought to influence cancer chemoprevention.
The ingestion of magnolol in humans is likely to be in the form of traditional Chinese medicine, known as kampo medicine in Japan. Here, we investigate the influence of the magnolol-containing kampo medicines Hange-koboku-to, Daijoki-to, and Goshaku-san, as well as Magnoliae Cortex, on clastogenesis induced by B(a)P. In package inserts of kampo treatments manufactured by Kotaro Kampo Pharmaceutical Co., Ltd., the anticipated indications of Hange-koboku-to included bronchitis, asthma, neurosis, neurasthenia, and insomnia; those for Dai-joki-to included constipation, hypertension, neurosis, and food poisoning; and those for Goshaku-san included gastritis, gastroptosis, backache, sciatica, and rheumatism.
Magnoliae Cortex accounts for 50% and 83% of the ingredients in Hange-koboku-to and Dai-joki-to, respectively, whereas it is only 11% in Goshaku-san. Comparing the inhibitory effects of these kampo medicines on clastogenicity may provide insight into their mode of action.
B(a)P is a ubiquitous aromatic polycyclic hydrocarbon encountered in daily life. It has been found in tobacco smoke and airborne particles as well as in industrial environments, particularly those dealing with coal tar and asphalt production. Atmospheric B(a)P is also suspected to be a food source contaminant.
14) B(a)P is a potent mutagen and carcinogen requiring metabolic activation, and its genotoxicity has been observed both in vivo and in vitro through the induction of genetic mutations and chromosome damage. [15] [16] [17] [18] Investigating the inhibitory effects of magnolol-containing medicines on B(a)P-induced clastogenicity is therefore of interest.
In this study, we investigated the in vivo anti-clastogenic effects of kampo medicines containing magnolol as well as Magnoliae Cortex on B(a)P-induced clastogenicity. Because B(a)P exhibits clastogenicity and is activated by CYP1A1, the in vivo anti-clastogenic mechanism of these medicines was investigated using an in vivo CYP1A1 inhibitory test involving the determination of zoxazolamine paralysis time.
MATERIALS AND METHODS
Animals Seven-week-old male ICR mice were purchased from Charles River Laboratories (Kanagawa, Japan) and used in experiments from eight weeks of age. All animals were housed in groups of four or six in mesh-bottomed stainless steel cages, with free access to food (CRF-1, Oriental Yeast, Tokyo, Japan) and tap water. The animal room was maintained at 23Ϯ2°C and 55Ϯ15% humidity, with a ventilation frequency of 15 In Vivo Micronucleus Test A micronucleus assay using peripheral blood cells was performed according to Hayashi et al. 19) B(a)P was administered once to mice at an dose of 100 mg/kg using a single intraperitoneal injection. Subsequently, Hange-koboku-to (high dose experiment: 100, 300, 1000, and 2000 mg/kg; low dose experiment: 10, 30, and 100 mg/kg), Dai-joki-to (10-2000 mg/kg, common ratio: 3), Goshaku-san (10-2000 mg/kg, common ratio: 3), or Magnoliae Cortex (5-1000 mg/kg, common ratio: 3) was then given by single oral administration. Forty-eight hours after B(a)P administration, approximately 5 ml of peripheral blood was taken from the tail vein and deposited on an acridine orange-coated glass slide. The slide was then covered with a cover glass to prepare peripheral blood specimens. Peripheral blood specimens were examined in a blinded manner using fluorescence microscopy (BHF/BH-RFL-LB, Olympus Corporation; Tokyo, Japan) at 600ϫ or higher magnification with a blue excitation wavelength (e.g,. 488 nm) and yellow to orange barrier filter (e.g., 515 nm long pass). One slide per animal was observed once by one observer who has sufficient experience of micronucleus test. The number of micronucleated reticulocytes (MNRETs) was measured at a rate of 2000 reticulocytes per animal. Statistical significance was evaluated using the Student's t-test.
The following equation was used to calculate the inhibition ratio: where A is the group treated with B(a)P (positive control), B the group treated with B(a)P and a Magnoliae cortexcontaining medicine, and C is the group treated with corn oil (negative control).
Zoxazolamine Paralysis Test
The in vivo inhibition of CYP1A1 activity by Hange-koboku-to, Dai-joki-to, Goshakusan, and Magnoliae Cortex was determined using the zoxazolamine paralysis test. 20) Zoxazolamine is a potent muscle relaxant that is metabolically inactivated by CYP1A1 enzyme activity, and to a lesser extent by CYP2E1.
Hange-koboku-to (10-2000 mg/kg, common ratio: 3), Dai-joki-to (10-2000 mg/kg, common ratio: 3), Goshakusan (10-2000 mg/kg, common ratio: 3), or Magnoliae Cortex (5-1000 mg/kg, common ratio: 3) was given to mice in a single oral administration, followed 30 min later by an intraperitoneal dose of 125 mg/kg zoxazolamine. Paralysis times were determined as the length of time required for the mice to regain their righting reflex. Statistical significance was evaluated using the Student's t-test.
The following equation was used to calculate the prolongation ratio:
prolongation ratioϭparalysis time upon treatment with medicineϬ paralysis time upon treatment with solvent
RESULTS
Clastogenicity of Hange-koboku-to, Dai-joki-to, Goshakusan, and Magnoliae Cortex The clastogenicity of Hangekoboku-to, Dai-joki-to, Goshaku-san, and Magnoliae Cortex in peripheral blood in vivo was determined using the mouse micronucleus test. The kampo medicines were administered at doses of 1000 and 2000 mg/kg and Magnoliae Cortex at 500 and 1000 mg/kg. Forty-eight hours after administration, peripheral blood was collected, and the prepared specimens were observed. Under these conditions, no clastogenicity was observed for any of the medicines (Tables 2-4) . a) The weights of dried extract from the mixture of the above plant in Hangekoboku-to, Dai-joki-to, and Goshaku-san were 6.0, 6.0, and 9.0 g, respectively.
Effect of Hange-koboku-to on Clastogenesis Induced by B(a)P The anti-clastogenic effect of Hange-koboku-to on B(a)P-induced micronuclei formation was investigated after administration at doses of 100, 300, 1000, and 2000 mg/kg. Hange-koboku-to inhibited B(a)P-induced micronucleus formation in a dose-dependent manner, with an inhibition ratio of approximately 50% at the lowest dose (100 mg/kg) ( Table  2) . We therefore investigated the inhibitory effect of Hangekoboku-to at lower doses (10, 30, 100 mg/kg). The results showed significant inhibition at 100 mg/kg, but that at 30 and 10 mg/kg was much lower ( Table 2) .
Effect of Dai-joki-to and Goshaku-san on Clastogenesis Induced by B(a)P The anti-clastogenic effect of Dai-jokito and Goshaku-san, which contain high and low levels of Magnoliae Cortex, respectively, was investigated after administration of the compound at doses of 10, 30, 100, 300, 1000, and 2000 mg/kg. Dai-joki-to inhibited clastogenicity in a dose-dependent manner, even at the lower dose levels of 10 and 30 mg/kg (Table 3 ). In contrast, Goshaku-san exhibited little clastogenicity inhibition at the maximum dose of 2000 mg/kg and no inhibition at doses lower than 1000 mg/kg (Table 3) . 
Effect of Magnoliae Cortex on Clastogenesis Induced by B(a)P To determine how Magnoliae Cortex contributes to clastogenicity inhibition in
Hange-koboku-to, doses of 5, 15, 50, 150, 500, and 1000 mg/kg were set based on the amount of Magnoliae Cortex found in Hange-koboku-to. Significant clastogenicity inhibition was noted at doses of 15 mg/kg or more, but no inhibition was seen at 5 mg/kg (Table 4) . To determine whether the amount of Magnoliae Cortex in Hange-koboku-to contributes to the inhibition of B(a)P-induced clastogenesis, the contribution ratio was calculated by dividing the inhibition ratio of Magnoliae Cortex by the inhibition ratio of Hange-koboku-to obtained at equivalent doses of Magnoliae Cortex (estimated). Although the contribution ratio of Magnoliae Cortex in Hange-koboku-to was not proportional to the Hange-koboku-to dose, the results suggest that Magnoliae Cortex contributed to the inhibitory effect of Hange-koboku-to (Fig. 1) .
Inhibition of Hange-koboku-to, Dai-joki-to, Goshakusan, and Magnoliae Cortex on CYP1A1 Enzyme Activity in Vivo The paralysis times for Hange-koboku-to, Dai-jokito, Goshaku-san, and Magnoliae Cortex are presented in Table 5 . Pre-treatment with Hange-koboku-to at 30 mg/kg or more, Dai-joki-to at 300 mg/kg or more, Goshaku-san at 1000 mg/kg or more, or Magnoliae Cortex at 50 mg/kg or 1212 Vol. 32, No. 7 
Fig. 1. Contribution Ratio of the Anti-clastogenic Effect of Magnoliae Cortex in Hange-koboku-to
The contribution ratio at 100 mg/kg was taken from the low-dose study. Contribution ratio (%)ϭ(inhibitory effect ratio of Magnoliae Cortex/inhibitory effect ratio of Hangekoboku-to)ϫ100. more significantly prolonged mean paralysis time. In this in vivo assay, the CYP1A1-inhibiting potential of Magnoliae Cortex was greatest, followed by Hange-koboku-to, Dai-jokito, and Goshaku-san.
DISCUSSION
In this study, we evaluated the anti-clastogenic effect of Hange-koboku-to, Dai-joki-to, Goshaku-san, and Magnoliae Cortex on B(a)P-induced clastogenicity using the in vivo mouse micronucleus test. The results show that Hangekoboku-to and Dai-joki-to, which contain high levels of Magnoliae Cortex, inhibited clastogenicity in a dose-dependent manner. Similar results were obtained for Magnoliae Cortex. In contrast, Goshaku-san inhibited clastogenicity only slightly. Comparison of the inhibition ratios showed that Hange-koboku-to, Dai-joki-to, and Magnoliae Cortex, which contain high levels of magnolol, were strong inhibitors, whereas Goshaku-san, which contains a low level of magnolol, was a weak inhibitor (Fig. 2) . In addition, we previously found that magnolol at doses of 1, 10, and 100 mg/kg inhibits B(a)P-induced clastogenicity with inhibitory ratios of 26.7, 67.3, and 81.3%, respectively.
2) These results suggest that magnolol is an active component involved in the inhibition of B(a)P-induced clastogenicity.
Because Dai-joki-to contains more Magnoliae Cortex (83%) than Hange-koboku-to (50%), Dai-joki-to was initially thought to have a more potent inhibitory effect. However, the results show that components other than magnolol also contribute to the potency of Hange-koboku-to. Hange-koboku-to contains Pinelliae Tuber, Magnoliae Cortex, Poria, Zingiberis Rhizoma, and Perillae Herba. Studies have shown that Geiji-Bokryung-Hwan, which contains Poria inhibits tumor initiation by inhibiting cyclooxygenase 1 (COX-1) activity, 21) and that Zingiberis Rhizoma strongly inhibits the initiation and post-initiation stages of carcinogenesis induced by 1,2-dimethylhydrazine. 22) In addition, Perilla Herba was found to inhibit skin papillomas induced by 7,12-dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoylphorbol13acetate (TPA) in mice. 23) Based on these studies, each component of Hange-koboku-to might have anti-clastogenic effects or synergistic biological effects. Although Hangekoboku-to has not been reported to be involved in cancer chemoprevention, its anti-clastogenic activity shows sufficient cancer chemopreventative potential. In addition, the results show that the contribution of Magnoliae Cortex to inhibition is not proportional to the Hange-koboku-to dose. Although the reason is unclear, the results suggest that Magnoliae Cortex significantly contributes to the overall inhibitory effect of Hange-koboku-to.
During the toxicological investigation for this study, all clinical signs and gross pathology results obtained after administration of Hange-koboku-to, Dai-joki-to, Goshaku-san, or Magnoliae Cortex were normal. Kampo medicine is generally considered to naturally have moderate toxicological effects in animals; therefore, human toxicity is also believed to be moderate.
Magnolol inhibits the CYP1A1-and CYP1A2-related enzyme activities of ethoxyresorufin-O-deethylase (EROD) and methoxyresorufin-O-demethylase (MROD) dose-dependently in S9 (in vitro) 1) and has also been shown to inhibit CYP1A1 activity (in vivo) in the zoxazolamine paralysis test.
3) Therefore, the anti-clastogenic mechanism of the kampo medicines studied here may be due to the inhibition of CYP1A1, a metabolic B(a)P activation enzyme. For this reason, the in vivo inhibition of CYP1A1 was investigated by measuring zoxazolamine paralysis time. The results suggest that the anti-clastogenic effect of kampo medicines may be due to the significant inhibition of CYP1A1 activity in vivo. In particular, medicines containing high levels of magnolol showed strong in vivo CYP1A1 inhibition, which agrees with the anti-clastogenic observations. In contrast, although kampo medicines at low doses also had anti-clastogenic effects, no significant CYP1A1 inhibition was observed. One study reported that the level of 8-hydroxy-2Ј-deoxyguanosine (8-OHdG) in liver, kidney, and lung tissue increased when Sprague-Dawley rats were treated orally with B(a)P. 24) Another study showed that the anti-oxidative effect of magnolol is evidenced by its effective inhibition of UV-induced mutations in Salmonella typhimurium TA102. 5) In addition, we reported that magnolol inhibits X-ray-induced clastogenicity, the mechanism for which could involve reactive oxygen scavenging. 2) This suggests that the anti-clastogenic mechanism of kampo medicines at low doses may be triggered by active oxygen. In addition to magnolol, other components of kampo medicine might also have an anti-clastogenic effect at low doses via mechanisms other than CYP1A1 inhibition. However, these components and their mechanisms have not yet been elucidated.
In conclusion, Hange-koboku-to, Dai-joki-to, and Magnoliae Cortex, which contain high levels of magnolol, significantly inhibit clastogenesis induced by B(a)P and sufficiently inhibit in vivo CYP1A1 activity. However, Goshaku-san, which contains low levels of magnolol, has little inhibitory effect on clastogenicity and inhibits in vivo CYP1A1 activity only slightly. This suggests that magnolol is a major contributor to the inhibition of B(a)P-induced clastogenesis, and that kampo medicine containing high levels of magnolol possesses significant anti-clastogenic properties. Kampo medicines containing magnolol may therefore have potential as chemopreventative treatments for cancer. 
